# Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

> **NCT04609904** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2187 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** BGF MDI 320/28.8/9.6 μg
- **DRUG:** BGF MDI 320/14.4/9.6 μg
- **DRUG:** BFF MDI 320/9.6 μg
- **DRUG:** BFF pMDI 320/9 μg

## Key facts

- **NCT ID:** NCT04609904
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2025-03-20
- **Final completion:** 2025-03-20
- **Target enrollment:** 2187 (ACTUAL)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609904, "Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04609904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*